Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Akorn, Natco Pharma Add Products To API Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Akorn, Natco Pharma Add Products To API Supply Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Akorn, Inc. has added two injectable drug products to its API Supply and Margin Sharing Agreement with Natco Pharma Ltd. One of the ANDA drug products is for the prevention of nausea and vomiting associated with cancer chemotherapy, and the other product is for the reduction of renal toxicity and xerostomia in cancer patients undergoing chemotherapy and radiation. According to 2006 IMS data, the market size for the two finished products is approximately $433 million.

Under the agreement, Natco will be responsible for the supply of the API for both drug products. Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the U.S. and Canada.

Arthur S. Przybyl, Akorn’s president and chief executive officer stated, “We are excited to expand our business partnership with Natco Pharma. These two products will continue to build upon our anti-cancer drug product franchise.”

Rejeev Nannapaneni, Natco Pharma’s chief operating officer stated, “We are happy to continue this fruitful partnership with Akorn.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters